Endothelin receptor antagonists for pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular va...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés Español |
| Publicado: |
2013
|
| Acceso en línea: | Registro en Scopus Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 25429caa a22018737a 4500 | ||
|---|---|---|---|
| 001 | PAPER-24191 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205600.0 | ||
| 008 | 190411s2013 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-84883405936 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 041 | 0 | |a eng |a spa | |
| 100 | 1 | |a Bevacqua, R.J. | |
| 245 | 1 | 0 | |a Endothelin receptor antagonists for pulmonary arterial hypertension |
| 246 | 3 | 1 | |a Antagonistas de los receptores de la endotelina para la hipertensión arterial pulmonar |
| 260 | |c 2013 | ||
| 270 | 1 | 0 | |m Perrone, S. V.Montañeses 2325, Ciudad Autónoma de Buenos Aires CP: C1428AQK, Argentina; email: svperrone@netizen.com.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a D'Alonzo, G.G., Barst, R.J., Ayres, S.M., Survival in patients with primary pulmonary hypertension: Results from a natural prospective registry (1991) Ann Intern Med, 115, pp. 343-349 | ||
| 504 | |a Humbert, M., Sitbon, O., Chaouat, A., Pulmonary arterial hypertension in France: Results from a national registry (2006) Am J Respir Crit Care Med, 173, pp. 1023-1030 | ||
| 504 | |a Peacock, A.J., Murphy, N.F., McMurray, J.J., An epidemiological study of pulmonary arterial hypertension (2007) Eur Respir J, 30, pp. 104-109 | ||
| 504 | |a Thenappan, T., Shah, S.J., Rich, S., A USA-based registry for pulmonary arterial hypertension: 1982-2006 (2007) Eur Respir J, 30, pp. 1103-1110 | ||
| 504 | |a Lauga, A., D'Ortencio, A., Monitoreo de las presiones de la arteria pulmonar: Catéter de Swan-Ganz. Parte I (2007) Insuf Card, 2 (1), pp. 5-11 | ||
| 504 | |a Gaine, S.P., Rubin, L.J., Primary pulmonary hypertension (1998) Lancet, 352, pp. 719-725 | ||
| 504 | |a Bortman, G., Presentación clínica y clasificación actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 27-32 | ||
| 504 | |a Melero, M.J., Estado actual de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 23-26 | ||
| 504 | |a Thierer, J., Importancia del diagnóstico precoz en la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 52-58 | ||
| 504 | |a Barst, R.J., McGoon, M., Torbicki, A., Diagnosis and differential assessment of pulmonary hypertension (2004) J Am Coll Cardiol, 43, pp. 40S-47S | ||
| 504 | |a Baim, D.S., (2005) Grossman's Cardiac Catheterization, Angiography, and Intervention, , ed., 7th ed. Philadelphia, Penn: Lippincott/ Williams &Wilkins | ||
| 504 | |a Rich, S., McLaughhlin, V., Pulmonary Hypertension (2005) Braunwalds Heart Disease, pp. 1807-1842. , En:, Zioes D, Libby P, Bonow R, Braunwald E, eds. Elsevier Saunders, 7ed | ||
| 504 | |a McLaughlin, V.V., McGoon, M.D., Pulmonary arterial hypertension (2006) Circulation, 114, pp. 1417-1431 | ||
| 504 | |a Ruiz Cano, M.J., Tello, M.R., Delgado, J.F., Aproximación diagnóstica al paciente con hipertensión arterial pulmonar (2009) Tratado de hipertensión arterial pulmonar, pp. 71-96. , En:, Sueiro B, Gaudo JI, eds. Ars Médica Barcelona | ||
| 504 | |a Masuyama, T., Kodama, K., Kitakabe, A., Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure (1986) Circulation, 74, pp. 484-492 | ||
| 504 | |a Bichara, V.M., Tazar, J., Ventura, H.O., El ecocardiograma como herramienta para el diagnóstico y la evaluación de los pacientes con insuficiencia cardíaca (2010) Insuf Card, 5 (2), pp. 51-58 | ||
| 504 | |a Tazar, J., Haurigot, M.P., Caram, R., Haurigot, G.E., Función sistólica del ventrículo derecho en pacientes con hipertensión pulmonar: Análisis con strain y strain rate (2012) Insuf Card, 7 (3), pp. 109-116 | ||
| 504 | |a Berger, M., Haimowitz, A., van Tosh, A., Berdoff, R.L., Golberg, E., Quantitative assessment of pulmonary hypertension in patient with tricuspid regurgitation using continuous wave Doppler ultrasound (1985) J Am Coll Cardiol, 6 (2), pp. 359-365 | ||
| 504 | |a Simonneau, G., Robbins, I., Beghetti, M., Updated Clinical Classification of Pulmonary Hypertension (2009) J Am Coll Cardiol, 54, pp. S43-S54 | ||
| 504 | |a Hoeper, M.M., Barbera, J.A., Channick, R.N., Diagnosis, Assessment, and treatment of nonpulmonary arterial hypertension pulmonary hypertension (2009) J Am Coll Cardiol, 54, pp. S85-S96 | ||
| 504 | |a Naval, N., Clasificación actual de la hipertensión pulmonar (2011) Insuf Card, 6 (1), pp. 30-38 | ||
| 504 | |a Naval, N., Epidemiología de la hipertensión pulmonar (2010) Insuf Card, 5 (4), pp. 192-196 | ||
| 504 | |a Rubin, L.J., Primary pulmonary hypertension (1997) N Engl J Med, 336, pp. 111-117 | ||
| 504 | |a Fuster, V., Steele, P.M., Edwards, W.D., Primary pulmonary hypertension: Natural history and the importance of thrombosis (1984) Circulation, 70, pp. 580-587 | ||
| 504 | |a Simonneau, G., Galie, N., Rubin, L., Clinical classification of pulmonary hypertension (2004) J Am Coll Cardiol, 43 (SUPPL.), pp. S5-S12 | ||
| 504 | |a Rich, S., Dantzker, D.R., Ayres, S.M., Primary pulmonary hypertension. A national prospective study (1987) Ann Intern Med, 107, pp. 216-223 | ||
| 504 | |a Rich, S., (1998) Primary Pulmonary Hypertension: Executive Summary From the World Symposium on Primary Pulmonary Hypertension, , Evian, France: World Health Organization | ||
| 504 | |a Barimboim, E., Hipertensión pulmonar en las enfermedades del tejido conectivo: Nuevas perspectivas ante un problema de difícil resolución (2009) Insuf Card, 4 (3), pp. 101-106 | ||
| 504 | |a Sánchez Román, J., Diagnóstico y tratamiento de la hipertensión pulmonar en pacientes con esclerodermia (2012) Insuf Card, 7 (1), pp. 16-28 | ||
| 504 | |a Peacock, A.J., Treatment of pulmonary hypertension (2003) BMJ, 326, pp. 835-836 | ||
| 504 | |a McGoon, M., Gutterman, D., Steen, V., Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines (2004) Chest, 126, pp. 14S-34S | ||
| 504 | |a Badesch, D.B., Abman, S.H., Simonneau, G., Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines (2007) Chest, 131, pp. 1917-1928 | ||
| 504 | |a Bichara, V.M., Ventura, H.O., Perrone, S.V., Hipertensión pulmonar: La mirada del especialista (2011) Insuf Card, 6, pp. 65-79 | ||
| 504 | |a Mazzei, J.A., Cáneva, J.O., Perrone, S.V., Melero, M.J., Scali, J.J., Bortman, G., Actualización en el diagnóstico y tratamiento de la hipertensión pulmonar (2011) Medicina (B. Aires), 71 (SUPPL. 1), pp. 1-48 | ||
| 504 | |a Caroli, C., Yaman, B., Embón, M., Cohen Arazi, H., Perrone, S.V., Resonancia magnética nuclear en la evaluación de la hipertensión pulmonar (2009) Insuf Card, 4 (2), pp. 82-84 | ||
| 504 | |a Perrone, S.V., Estrategia terapéutica en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 33-43 | ||
| 504 | |a McLaughlin, V.V., Archer, S.L., Badesch, D.B., ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents (2009) J Am Coll Cardiol, 53, pp. 1573-1619 | ||
| 504 | |a Farber, H.W., Loscalzo, J., Pulmonary arterial hypertension (2004) N Engl J Med, 351, pp. 1655-1665 | ||
| 504 | |a Badesch, D.B., Champion, H.C., Gomez Sanchez, M.A., Diagnosis and assessment of pulmonary arterial hypertension (2009) J Am Coll Cardiol, 54, pp. S55-S66 | ||
| 504 | |a Mazzei, J.A., Mecanismos fisiopatológicos involucrados y diagnóstico de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 3-10 | ||
| 504 | |a Wigley, F.M., Lima, J.A., Mayes, M., The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study) (2005) Arthritis Rheum, 52, pp. 2125-2132 | ||
| 504 | |a Koh, E.T., Lee, P., Gladman, D.D., Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients (1996) Br J Rheumatol, 35, pp. 989-993 | ||
| 504 | |a Vongpatanasin, W., Brickner, M., Hillis, L.D., The Eisenmenger Syndrome in adults (1998) Ann Intern Med, 128, pp. 745-755 | ||
| 504 | |a Cappola, T.P., Felker, G.M., Kao, W.H., Pulmonary hypertension and risk of death in cardiomyopathy (2002) Circulation, 105, pp. 1663-1668 | ||
| 504 | |a Krowka, M.J., Hepatopulmonary syndromes (2000) Gut, 46, pp. 1-4 | ||
| 504 | |a Newman, J.H., Fanburg, B.L., Archer, S.L., Pulmonary arterial hypertension: Future directions: Reports of a National Heart, Lung and Blood Institute/Office of Rare Disease Workshop (2004) Circulation, 109, pp. 2947-2952 | ||
| 504 | |a Lepetit, H., Eddahibi, S., Fadel, E., Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension (2005) Eur Respir J, 25, pp. 834-842 | ||
| 504 | |a Begnini, A., Remuzzi, G., Endothelin antagonists (1999) Lancet, 353, pp. 133-138 | ||
| 504 | |a Giaid, A., Yanagisawa, M., Langleben, D., Expression of endothelin-1in the lungs of patients of pulmonary hypertension (1993) N Engl J Med, 328, pp. 1732-1739 | ||
| 504 | |a Stewart, D.J., Levy, R.D., Cernacek, P., Increase plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? (1991) Ann Intern Med, 114, pp. 464-469 | ||
| 504 | |a Tuder, R.M., Cool, C.D., Geraci, M.W., Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension (1999) Am J Respir Crit Care Med, 159, pp. 1925-1932 | ||
| 504 | |a Cristman, B.W., McPherson, C.D., Newman, J.H., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension (1992) N Engl J Med, 237, pp. 70-75 | ||
| 504 | |a Giaid, A., Saleh, D., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension (1993) N Engl J Med, 333, pp. 214-221 | ||
| 504 | |a Cella, G., Bellotto, F., Toma, F., Plasma markers of endothelial dysfunction in pulmonary hypertension (2001) Chest, 120, pp. 1226-1230 | ||
| 504 | |a Lincoln, T.M., Cyclic GMP and phosphodiesterase 5 inhibitor therapies: What's on the horizon? (2004) Mol Pharmacol, 66, pp. 11-13 | ||
| 504 | |a Eddahibbi, S., Humbert, M., Fadel, E., Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension (2001) J Clin Invest, 108, pp. 1141-1150 | ||
| 504 | |a Guignabert, C., Izikki, M., Ieng, L., Transgenic mice overexpressing the 5-Hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension (2006) Circ Res, 98, pp. 1323-1330 | ||
| 504 | |a Petkov, V., Mosgeoller, W., Ziesche, R., Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension (2003) J Clin Invest, 111, pp. 1339-1346 | ||
| 504 | |a Eddahibbi, S., Morrell, N., D'Ortho, M.-P., Pathobiology of pulmonary arterial hypertension (2002) Eur Respir J, 20, pp. 1559-1572 | ||
| 504 | |a Rich, S., Primary pulmonary hypertension (1988) Prog Cardiovasc Dis., 31, pp. 205-238 | ||
| 504 | |a Davie, N., Haleen, S.J., Upton, P.D., ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells (2002) Am J Respir Crit Care Med, 165, pp. 398-405 | ||
| 504 | |a Nishida, M., Eshiro, K., Okada, Y., Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats (2004) J Cardiovasc Pharmacol, 44, pp. 187-191 | ||
| 504 | |a Sauvageau, S., Thorin, E., Caron, A., Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions (2007) J Vasc Res, 44, pp. 375-381 | ||
| 504 | |a Sauvageau, S., Thorin, E., Caron, A., Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction (2006) Exp Biol Med (Maywood), 231, pp. 840-846 | ||
| 504 | |a McLean, M.R., Docherty, C.C., McCulloch, K.M., Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries (1998) Pulm Pharmacol Ther, 11, pp. 147-149 | ||
| 504 | |a Jasmin, J.F., Lucas, M., Cernacek, P., Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension (2001) Circulation, 103, pp. 314-318 | ||
| 504 | |a Dupuis, J., Hoeper, M.M., Endothelin receptor antagonists in pulmonary arterial hypertension (2008) Eur Respir J, 31, pp. 407-415 | ||
| 504 | |a Rosenblum, W.D., Pulmonary Arterial Hypertension. Pathobiology, Diagnosis, Treatment, and Emerging Therapies (2010) Cardiology in Review, 18, pp. 58-63 | ||
| 504 | |a Williamson, D.J., Wallman, L.L., Jones, R., Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension (2000) Circulation, 102, pp. 411-418 | ||
| 504 | |a Channick, R.N., Simonneau, G., Sitbon, O., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study (2001) Lancet, 358, pp. 1119-1123 | ||
| 504 | |a Grignola, J.C., Gómez Sánchez, M.A., Bosentan: Rol en el tratamiento de la hipertensión arterial pulmonar (2009) Insuf Card, 4 (1), pp. 11-22 | ||
| 504 | |a Kaplinsky, E.J., Utilidad del bosentan en la hipertensión pulmonar tromboembólica crónica: Estudio BENEFIT (2008) Insuf Card, 3 (2), pp. 63-64 | ||
| 504 | |a Rubin, L.J., Badesch, D.B., Barst, R.J., Bosentan therapy for pulmonary arterial hypertension (2002) N Engl J Med, 346, pp. 846-903 | ||
| 504 | |a Galiè, N., Rubin, L.J., Hoeper, M.M., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial (2008) Lancet, 371, pp. 2093-2100 | ||
| 504 | |a McLaughlin, V.V., Sitbon, O., Badesch, D.B., Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) Eur Respir J, 25, pp. 244-249 | ||
| 504 | |a Provencher, S., Sitbon, O., Humbert, M., Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension (2006) Eur Heart J, 27, pp. 589-595 | ||
| 504 | |a Keogh, A.M., McNeil, K.D., Wlodarczyk, J., Quality of life in pulmonary arterial hypertension: Improvement and maintenance with bosentan (2007) J Heart Lung Transplant, 26, pp. 181-187 | ||
| 504 | |a Barst, R.J., Ivy, D., Dingemanse, J., Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension (2003) Clin Pharmacol Ther, 73, pp. 372-382 | ||
| 504 | |a Rosenzweig, E.B., Ivy, D.D., Widlitz, A., Effects of longterm bosentan in children with pulmonary arterial hypertension (2005) J Am Coll Cardiol, 46, pp. 697-704 | ||
| 504 | |a Sitbon, O., Gressin, V., Speich, R., Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension (2004) Am J Respir Crit Care Med, 170, pp. 1212-1217 | ||
| 504 | |a Degano, B., Yaïci, A., le Pavec, J., Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension (2009) Eur Respir J, 33, pp. 92-98 | ||
| 504 | |a Galiè, N., Beghetti, M., Gatzoulis, M.A., Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind, randomized, placebo-controlled study (2006) Circulation, 114, pp. 48-54 | ||
| 504 | |a Denton, C.P., Humbert, M., Rubin, L., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions (2006) Ann Rheum Dis, 65, pp. 1336-1340 | ||
| 504 | |a Wilkins, M.R., Paul, G.A., Strange, J.W., Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study (2005) Am J Respir Crit Care Med, 171, pp. 1292-1297 | ||
| 504 | |a Galiè, N., Badesch, D., Oudiz, R., Ambrisentan therapy for pulmonary arterial hypertension (2005) J Am Coll Cardiol, 46, pp. 529-535 | ||
| 504 | |a Galiè, N., Olschewski, H., Oudiz, R.J., Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 (2008) Circulation, 117, pp. 3010-3019 | ||
| 504 | |a Oudiz, R.J., Galiè, N., Olschewski, H., Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension (2009) J Am Coll Cardiol, 54, pp. 1971-1981 | ||
| 504 | |a Badesch, D.B., Feldman, J., Keogh, A., ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract] (2009) Am J Respir Crit Care Med, 179, pp. A3357 | ||
| 504 | |a (2009) Tracleer prescribing information, , South San Francisco, CA: Actelion Pharmaceuticals | ||
| 504 | |a Humbert, M., Segal, E.S., Kiely, D.G., Results of European post-marketing surveillance of bosentan in pulmonary hypertension (2007) Eur Respir J, 30, pp. 338-344 | ||
| 504 | |a McGoon, M.D., Frost, A.E., Oudiz, R.J., Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities (2009) Chest, 135, pp. 122-129 | ||
| 504 | |a Paul, G.A., Gibbs, J.S., Boobis, A.R., Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension (2005) Br J Clin Pharmacol, 60, pp. 107-112 | ||
| 504 | |a Ghofrani, H.A., Rose, F., Schermuly, R.T., Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension (2003) J Am Coll Cardiol, 42, pp. 158-164 | ||
| 504 | |a Hoeper, M.M., Faulenbach, C., Golpon, H., Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension (2004) Eur Respir J, 24, pp. 1007-1010 | ||
| 504 | |a Hoeper, M.M., Taha, N., Bekjarova, A., Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids (2003) Eur Resp J, 22, pp. 330-334 | ||
| 504 | |a Humbert, M., Barst, R.J., Robbins, I.M., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004) Eur Respir J, 24, pp. 353-359 | ||
| 504 | |a McLaughlin, V.V., Oudiz, R.J., Frost, A., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension (2006) Am J Respir Crit Care Med, 174, pp. 1257-1263 | ||
| 504 | |a Hoeper, M.M., Leuchte, H., Wilkens, H., Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension (2006) Eur Resp J, 28, pp. 691-694 | ||
| 504 | |a Mathai, S.C., Girgis, R.E., Fisher, M.R., Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension (2007) Eur Respir J, 29, pp. 469-475 | ||
| 504 | |a Savale, L., Sitbon, O., le Pavec, J., Addition of sildenafil to first line bosentan therapy in patients with idiopathic pulmonary arterial hypertension [abstract] (2009) Am J Respir Crit Care Med, 179 (SUPPL.), pp. A3368 | ||
| 504 | |a Simonneau, G., Rubin, L.J., Galiè, N., Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (2008) Ann Intern Med, 149, pp. 521-530 | ||
| 504 | |a Bendayan, D., Shitrit, D., Kramer, M.R., Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: A pilot study (2008) Respirology, 13, pp. 916-918 | ||
| 504 | |a Hoeper, M.M., Faulenbach, C., Golpon, H., Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension (2004) Eur Respir J, 24, pp. 1007-1010. , Abstract | ||
| 504 | |a Mathai, S.C., Girgis, R.E., Fisher, M.R., Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension (2007) Eur Respir J, 29, pp. 469-475 | ||
| 504 | |a Gruenig, Michelakis, Vachiery, COMPASS-1 (2007) Eur Heart J, 28 (SUPPL.), p. 140 | ||
| 504 | |a Torres, F., Gupta, H., Murali, S., Goal-directed combination therapy in pulmonary arterial hypertension (PAH): Study design of COMPASS-3 (2007) Chest, 132, pp. 633S | ||
| 504 | |a Benza, R.L., Gupta, H., Soto, F.J., Park, M.H., Torres, F., Frey, N., Murali, S., Safety and Efficacy of Bosentan in Combination With Sildenafil in PAH Patients Who Experience Inadequate Clinical Response to Monotherapy: The COMPASS-3 Study (2010) Chest, 138 (4), pp. 840A. , MeetingAbstracts | ||
| 504 | |a Kawut, S.M., Palevsky, H.I., Surrogate end points for pulmonary arterial hypertension (2004) Am Heart J, 148, pp. 559-565. , Abstract | ||
| 504 | |a Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (COMPASS 2), , http://www.clinicaltrials.gov/ct2/show/NCT00303459, Available at: | ||
| 504 | |a Humbert, M., Barst, R.J., Robbins, I.M., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 (2004) Eur Respir J, 24, pp. 353-359. , Abstract | ||
| 504 | |a McLaughlin, V.V., Oudiz, R.J., Frost, A., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension (2006) Am J Respir Crit Care Med, 174, pp. 1257-1263. , Abstract | ||
| 504 | |a Frost, A.E., Step-open label extension: Long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension (PAH) (2007) Am J Resp Crit Care Med, 175, pp. A1001. , the Step Investigators | ||
| 504 | |a McLaughlin, V., Rubin, L., Benza, R., TRIUMPH 1: Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (2008) Am Rev Resp Crit Care Med, 177, pp. A965 | ||
| 504 | |a Hoeper, M.M., Markevych, I., Spiekerkoetter, E., Goaloriented treatment and combination therapy for pulmonary arterial hypertension (2005) Eur Respir J, 26, pp. 858-863 | ||
| 504 | |a Galie, N., Manes, A., Negro, L., A meta-analysis of randomized controlled trials in pulmonary arterial hypertension (2009) Eur Heart J, 30, pp. 394-403 | ||
| 504 | |a Sitbon, O., Morrell, N.W., Pathways in pulmonary arterial hypertension: The future is here (2012) Eur Respir Rev, 21 (126), pp. 321-327 | ||
| 504 | |a Humbert, M., Souza, R., Galiè, N., McLaughlin, V., Simonneau, G., Rubin, L., Pulmonary arterial hypertension: Bridging the present to the future (2012) Eur Respir Rev, 21 (126), pp. 267-270 | ||
| 520 | 3 | |a Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular vasoconstriction, smooth muscle cell proliferation, and thrombosis. These changes are a result of an imbalance between vasodilators (prostacyclin, nitric oxide, vasoactive intestinal peptide) and vasoconstrictors (thromboxane A2, endothelin, serotonin), growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors. Recent advances in treatment are directed at restoring the balance between these systems. Endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil), and prostacylin (epoprostenol, iloprost, treprostinil, beraprost) represent the different classes of medications that are currently used in monotherapy and in combination to treat PAH. The purpose of this review is to provide the reader with an update on the treatment of PAH with antagonists of endothelin receptors. © 2013 Silver Horse. |l eng | |
| 593 | |a División Cardiología, Pabellón Inchauspe, Hospital General de Agudos 'Dr. José María Ramos Mejía', GCBA, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Insuficiencia cardíaca, Hipertensión pulmonar, Trasplante cardíaco, Sanatorio de la Trinidad-Mitre, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Insuficiencia cardíaca, Hipertensión pulmonar, Trasplante cardíaco, Instituto FLENI, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Hospital de Alta Complejidad 'Pte. Juan Domingo Perón', Formosa, Formosa, Argentina | ||
| 593 | |a Instituto Argentino de Diagnóstico y Tratamiento, Ciudad de Buenos Aires, Argentina | ||
| 593 | |a Hospital Alta Complejidad en Red El Cruce 'Dr. Néstor Carlos Kirchner', Florencio Varela, Buenos Aires, Argentina | ||
| 593 | |a Instituto Cardiovascular Lezica, San Isidro, Buenos Aires, Argentina | ||
| 593 | |a Hospital Italiano de Mendoza, Mendoza, Argentina | ||
| 690 | 1 | 0 | |a AMBRISENTAN |
| 690 | 1 | 0 | |a BOSENTAN |
| 690 | 1 | 0 | |a COMBINATION THERAPY |
| 690 | 1 | 0 | |a ENDOTHELIN RECEPTOR ANTAGONIST |
| 690 | 1 | 0 | |a PATHOPHYSIOLOGICAL PATHWAYS |
| 690 | 1 | 0 | |a PULMONARY ARTERIAL HYPERTENSION |
| 700 | 1 | |a Bortman, G. | |
| 700 | 1 | |a Perrone, S.V. | |
| 773 | 0 | |d 2013 |g v. 8 |h pp. 77-94 |k n. 2 |p Insuficiencia Cardiaca |x 18501044 |w (AR-BaUEN)CENRE-8510 |t Insuficiencia Cardiaca | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883405936&partnerID=40&md5=c03034895c7eb0dcf7e7216321d4a31d |y Registro en Scopus |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_18501044_v8_n2_p77_Bevacqua |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_18501044_v8_n2_p77_Bevacqua |y Registro en la Biblioteca Digital |
| 961 | |a paper_18501044_v8_n2_p77_Bevacqua |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 85144 | ||